Article
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2022
Xiong Anwen, Ren Shengxiang, Liu Huaimin, Miao Liyun, Wang Lei, Chen Jianhua, Li Wei, Li Runpu, Wang Xiang, Lu Zhiwei, Wang Donglin, Wu Xiaohong, Liu Zhihua, Xing Ligang, Mao Yimin, Liu Chunling, Zeng Aiping, Niu Hongrui, Du Yingying, Sun Yuping, Pan Yueyin, Hu Yanping, Zhang Xiaodong, Chen Xueqin, Ma Zhiyong, Li Na, Zhang Jianyong, Zhao Min, Li Xiaoling, Ye Feng, Li Mingjun, Yu Guohua, Zhang Xiaomeng, Min Jie, Han Dong, Li Jin, Zhou Caicun
Abstract excerpt
INTRODUCTION: As a novel third-generation EGFR tyrosine kinase inhibitor (TKI), SH-1028 (formerly oritinib) is developed to inhibit both sensitizing EGFR mutations and EGFR T790M mutation. METHODS: This was a multicenter, single-arm, open-label, phase 2 trial (NCT03823807). Eligible patients were those with advanced NSCLC with centrally confirmed EGFR T790M mutation who progressed after first- or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.